NOMADX Holdings Launches Early Access Program for its Pioneering Hand-Held Food Pathogen Detection Platform
06 Mayo 2024 - 10:30AM
Business Wire
Portable enhanced SERS technology powers the PCR-equivalent (or
greater) sensitivity and resulting identification of harmful food
pathogens, categorically, in the various links in the chain from
“seed to shelves” within a minute of sample preparation
NOMADX Holdings, LLC, a company pioneering new technologies for
biological and chemical detection, announced today that it has
initiated an early access program for its portable NOMADX platform
which aims to enable faster, more accurate on-site pathogen
detection in food safety applications. The company will present, as
a platinum sponsor, an overview of the NOMADX platform at the Food
Safety Summit taking place May 6-9, 2024, in Rosemont, Illinois,
while discussing its current and future technology and autonomous
pipeline applications.
Powered by technology originally licensed from a leading
university, but modified thereafter, the NOMADX cartridge-enhanced
SERS platform is a patented surface coating that is applied to
silicon chips using metallic nanoparticles. The novel technology
significantly enhances the electromagnetic and chemical spectral
scattering signal of molecules within a sample to create a
platform. Internal validation studies have demonstrated that these
enhancements allow the detection and quantification of a wide range
of analytes at single-molecule detection levels. However, further
studies have shown that NOMADX is as fast and simple to use as an
ATP-based test, with results that can exceed the sensitivity,
specificity, and speed (1-minute results) of traditional PCR
testing.
"The food industry stands to benefit immensely from
technological innovations that enable more accurate testing methods
that can be performed by anyone. Traditional approaches, such as
quantitative PCR assays and DNA sequencing, often suffer from
delays due to centralized processing requirements and complicated
sample prep protocols,” said Rupesh Chaturvedi, Ph.D., Scientific
Advisor to NOMADX Holdings LLC. “The NOMADX platform addresses this
challenge by leveraging a cutting-edge cartridge-based technology,
providing decentralized, on-site testing capabilities that
significantly enhance the pace and accuracy of food safety
assessments."
In the United States, the Centers for Disease Control and
Prevention estimates that approximately 1 in 6 Americans —nearly 48
million people— gets sick each year with nearly 128,000
hospitalizations, and 3,000 deaths from foodborne diseases.
[Source] This is a preventable public health challenge and
multi-billion dollar burden. The World Health Organization
estimates that globally, foodborne illness effects an estimated 600
million —almost 1 in 10 people— in the world who fall ill after
eating contaminated food and 420,000 die every year, resulting in
the loss of 33 million healthy life years. Currently, quantitative
PCR assays and DNA sequencing are the most common methods used to
detect pathogens and identify food components. These methods,
however, often require specialized technical expertise and sample
shipment to a central processing lab with results being delivered
up to days or weeks later. Technologies that enable decentralized,
onsite testing have the potential to increase the pace of testing
and further ensure that food products are pathogen-free and safe
for consumption.
“As foodborne illnesses continue to pose a significant threat to
public health, there is an urgent need for better testing methods
to mitigate risks and ensure consumer safety. The NOMADX platform's
ability to deliver rapid, on-site pathogen detection represents a
crucial evolution in this regard, offering faster and more accurate
results without the need for extensive laboratory infrastructure or
specialized training,” said Anjan Chatterji, JD, MBA, LLM, Chief
Executive Officer and Co-Founder of NOMADX Holdings.
The NOMADX sample collection protocol is designed for use by
technicians and non-technical individuals alike and is similar to
an ATP test where a wetted swab is used to sample a defined
surface. The collected sample is then deposited into a cartridge,
which contains the patented chip. Each cartridge is read by the
hand-held device in under one minute and delivers laboratory-grade
results. Further, spectral data are analyzed with the NOMADX data
library and AI-based algorithms to produce results instantly. The
cartridge and sample can be retained for confirmatory testing, as
this NOMADX protocol is non-destructive to the sample. All testing
can be performed at the point of sampling without the need for
laboratory equipment or specialized training.
The early access program is open to grower/farmer, food
processor, distribution, retail/foodservice, and regulatory
organizations seeking an innovative new pathogen testing solution.
For more information on the NOMADX early access program, please
visit: www.nomadxholdings.com/earlyaccess.
About NOMADX Holdings
NOMADX Holdings LLC, is pioneering new technologies for
biological and chemical detection that include innovative products
that will enable faster, more accurate testing in food, water, and
air safety as well as human healthcare, applications. For more
information about NOMADX and its mission to become the natural
selection in the evolution of diagnostics, please visit
www.nomadxholdings.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506019822/en/
media@nomadxholdings.com